Concerns regarding use of patient-reported outcomes in biomarker studies of chemotherapy-induced peripheral neuropathy

Paclitaxel Plasma Concentration after the First Infusion Predicts Treatment-Limiting Peripheral Neuropathy

(2018) Daniel L. Hertz et al.   CLINICAL CANCER RESEARCH

Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment

(2017) Ethan Basch et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Exploring differences in adverse symptom event grading thresholds between clinicians and patients in the clinical trial setting

(2017) Thomas M. Atkinson et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy

(2016) D. L. Hertz et al.   CLINICAL CANCER RESEARCH

Patient-reported outcomes in the evaluation of toxicity of anticancer treatments

(2016) Massimo Di Maio et al.   Nature Reviews Clinical Oncology

Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199

(2015) B. P. Schneider et al.   CLINICAL CANCER RESEARCH

Identifying Predictors of Taxane-Induced Peripheral Neuropathy Using Mass Spectrometry-Based Proteomics Technology

(2015) Emily I. Chen et al.   PLoS One

Sequencing of Charcot-Marie-Tooth disease genes in a toxic polyneuropathy

(2014) Andreas S. Beutler et al.   ANNALS OF NEUROLOGY

A Genome-Wide Association Study Identifies Novel Loci for Paclitaxel-Induced Sensory Peripheral Neuropathy in CALGB 40101

(2012) R. M. Baldwin et al.   CLINICAL CANCER RESEARCH

Reliability of adverse symptom event reporting by clinicians

(2011) Thomas M. Atkinson et al.   QUALITY OF LIFE RESEARCH

Adverse Symptom Event Reporting by Patients vs Clinicians: Relationships With Clinical Outcomes

(2009) Ethan Basch et al.   JNCI-Journal of the National Cancer Institute